vs
Side-by-side financial comparison of Eightco Holdings Inc. (ORBS) and TriSalus Life Sciences, Inc. (TLSI). Click either name above to swap in a different company.
TriSalus Life Sciences, Inc. is the larger business by last-quarter revenue ($13.2M vs $10.2M, roughly 1.3× Eightco Holdings Inc.). TriSalus Life Sciences, Inc. runs the higher net margin — -73.9% vs -2281.6%, a 2207.8% gap on every dollar of revenue. On growth, TriSalus Life Sciences, Inc. posted the faster year-over-year revenue change (59.8% vs -49.9%). TriSalus Life Sciences, Inc. produced more free cash flow last quarter ($-2.5M vs $-11.0M). Over the past eight quarters, TriSalus Life Sciences, Inc.'s revenue compounded faster (43.0% CAGR vs 13.1%).
TriSalus Life Sciences, Inc. is a clinical-stage biotechnology company focused on advancing immuno-oncology and interventional oncology solutions. It develops proprietary targeted drug delivery technologies designed to improve treatment efficacy for patients with liver, pancreatic and other hard-to-treat solid tumors, primarily operating in North American markets via partnerships with clinical care and research institutions.
ORBS vs TLSI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.2M | $13.2M |
| Net Profit | $-232.5M | $-9.8M |
| Gross Margin | -13.0% | 86.7% |
| Operating Margin | -475.0% | -24.8% |
| Net Margin | -2281.6% | -73.9% |
| Revenue YoY | -49.9% | 59.8% |
| Net Profit YoY | -9183.3% | 3.5% |
| EPS (diluted) | $-2.34 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $10.2M | $13.2M | ||
| Q3 25 | $5.3M | $11.6M | ||
| Q2 25 | $7.6M | $11.2M | ||
| Q1 25 | $9.9M | $9.2M | ||
| Q4 24 | $20.3M | $8.3M | ||
| Q3 24 | $6.1M | $7.3M | ||
| Q2 24 | $5.3M | $7.4M | ||
| Q1 24 | $8.0M | $6.5M |
| Q4 25 | $-232.5M | $-9.8M | ||
| Q3 25 | $-25.8M | $-10.8M | ||
| Q2 25 | $-1.2M | $-8.3M | ||
| Q1 25 | $-2.5M | $-10.4M | ||
| Q4 24 | $-2.5M | $-10.1M | ||
| Q3 24 | $-3.2M | $-2.4M | ||
| Q2 24 | $4.4M | $-4.3M | ||
| Q1 24 | $1.9M | $-13.2M |
| Q4 25 | -13.0% | 86.7% | ||
| Q3 25 | -3.7% | 83.5% | ||
| Q2 25 | 16.4% | 83.9% | ||
| Q1 25 | 8.2% | 83.7% | ||
| Q4 24 | 8.2% | 85.3% | ||
| Q3 24 | 26.5% | 86.3% | ||
| Q2 24 | 25.1% | 87.6% | ||
| Q1 24 | 17.5% | 85.0% |
| Q4 25 | -475.0% | -24.8% | ||
| Q3 25 | -116.9% | -77.9% | ||
| Q2 25 | -15.9% | -65.4% | ||
| Q1 25 | -14.3% | -79.9% | ||
| Q4 24 | -11.9% | -91.8% | ||
| Q3 24 | -29.1% | -118.9% | ||
| Q2 24 | -16.4% | -111.0% | ||
| Q1 24 | -39.6% | -180.8% |
| Q4 25 | -2281.6% | -73.9% | ||
| Q3 25 | -487.6% | -93.5% | ||
| Q2 25 | -15.4% | -73.9% | ||
| Q1 25 | -25.7% | -113.2% | ||
| Q4 24 | -12.3% | -122.4% | ||
| Q3 24 | -52.5% | -32.6% | ||
| Q2 24 | 84.2% | -58.8% | ||
| Q1 24 | 24.4% | -204.5% |
| Q4 25 | $-2.34 | $-0.22 | ||
| Q3 25 | $-0.58 | $-0.96 | ||
| Q2 25 | $-0.38 | $-0.27 | ||
| Q1 25 | $-0.84 | $-0.39 | ||
| Q4 24 | $-1.44 | $-0.38 | ||
| Q3 24 | $-1.77 | $-0.12 | ||
| Q2 24 | $2.15 | $-0.21 | ||
| Q1 24 | $1.42 | $-0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $58.5M | $20.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $232.6M | $-33.9M |
| Total Assets | $250.2M | $35.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $58.5M | $20.4M | ||
| Q3 25 | $23.7M | $22.7M | ||
| Q2 25 | $696.3K | $26.5M | ||
| Q1 25 | $434.4K | $13.0M | ||
| Q4 24 | $239.2K | $8.5M | ||
| Q3 24 | $2.4M | $11.3M | ||
| Q2 24 | $363.1K | $16.5M | ||
| Q1 24 | $808.8K | $4.0M |
| Q4 25 | $232.6M | $-33.9M | ||
| Q3 25 | $339.2M | $-26.7M | ||
| Q2 25 | $8.9M | $-19.4M | ||
| Q1 25 | $9.7M | $-34.4M | ||
| Q4 24 | $11.9M | $-25.9M | ||
| Q3 24 | $13.0M | $-20.4M | ||
| Q2 24 | $13.8M | $-25.3M | ||
| Q1 24 | $3.9M | $-36.0M |
| Q4 25 | $250.2M | $35.3M | ||
| Q3 25 | $355.5M | $36.5M | ||
| Q2 25 | $48.7M | $41.3M | ||
| Q1 25 | $47.6M | $28.6M | ||
| Q4 24 | $50.8M | $24.0M | ||
| Q3 24 | $49.2M | $27.5M | ||
| Q2 24 | $48.4M | $32.4M | ||
| Q1 24 | $50.2M | $17.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.0M | $-2.5M |
| Free Cash FlowOCF − Capex | $-11.0M | $-2.5M |
| FCF MarginFCF / Revenue | -107.7% | -19.1% |
| Capex IntensityCapex / Revenue | 0.0% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-19.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.0M | $-2.5M | ||
| Q3 25 | $-1.6M | $-3.7M | ||
| Q2 25 | $-659.2K | $-7.3M | ||
| Q1 25 | $999.8K | $-4.5M | ||
| Q4 24 | $-6.6M | $-5.7M | ||
| Q3 24 | $77.7K | $-10.8M | ||
| Q2 24 | $-440.3K | $-13.4M | ||
| Q1 24 | $-723.3K | $-10.9M |
| Q4 25 | $-11.0M | $-2.5M | ||
| Q3 25 | — | $-3.9M | ||
| Q2 25 | $-661.3K | $-7.4M | ||
| Q1 25 | $999.7K | $-5.3M | ||
| Q4 24 | $-6.6M | $-5.8M | ||
| Q3 24 | $73.0K | $-11.0M | ||
| Q2 24 | — | $-13.5M | ||
| Q1 24 | — | $-10.9M |
| Q4 25 | -107.7% | -19.1% | ||
| Q3 25 | — | -33.9% | ||
| Q2 25 | -8.7% | -66.1% | ||
| Q1 25 | 10.1% | -57.3% | ||
| Q4 24 | -32.7% | -69.7% | ||
| Q3 24 | 1.2% | -149.9% | ||
| Q2 24 | — | -183.1% | ||
| Q1 24 | — | -169.3% |
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | 0.0% | 1.9% | ||
| Q2 25 | 0.0% | 0.8% | ||
| Q1 25 | 0.0% | 8.2% | ||
| Q4 24 | 0.0% | 0.6% | ||
| Q3 24 | 0.1% | 2.3% | ||
| Q2 24 | — | 0.8% | ||
| Q1 24 | — | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -0.10× | — | ||
| Q1 24 | -0.37× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
